title: Do All High- and Intermediate-Risk Patients With Metastatic Castration-Resistant Prostate Cancer Really Benefit From Abiraterone?
authors.affiliation: Bristol Cancer Institute, Bristol, United Kingdom Alfredo.Addeo@UHBristol.nhs.uk.
authors.forename: Alfredo
authors.initials: A
authors.lastname: Addeo
authors.affiliation: Bristol Cancer Institute, Bristol, United Kingdom.
authors.forename: Amit
authors.initials: A
authors.lastname: Bahl
mesh_terms: D000736:Androstenes / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D006801:Humans; D008297:Male; D009360:Neoplastic Cells, Circulating / Q000473:pathology*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000473:pathology*
chemical_list: D000736:Androstenes; D014408:Biomarkers, Tumor